CD4saurus Rex &HIVelociraptor vs. development of clinically useful immunological markers: A Jurassic tale of frozen evolution

Journal of Translational Medicine

Volumn 9, Issue 1, 2011, Pages

  De Maria, Andrea ^a,b   Cossarizza, Andrea ^c,d  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Antiviral treatment; CD4+T cells; Clinical trials; Immune reconstitution

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER;

CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; DISEASE MARKER; FLOW CYTOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL TECHNIQUE; INNATE IMMUNITY; KAPOSI SARCOMA; LYMPHOMA; NOTE; PROMYELOCYTIC LEUKEMIA; QUALITY CONTROL; RELIABILITY; STANDARDIZATION; TUBERCULOSIS; VIRUS IMMUNITY; COMPARATIVE STUDY; EDITORIAL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; METABOLISM; METHODOLOGY; PATHOLOGY;

BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HUMANS;

EID: 79959216008     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-93     Document Type: Note

References (75)

1. Guatelli J. How Innate Immunity Can Inhibit the Release of HIV-1 from Infected Cells. New England Journal of Medicine 362:553-554. 10.1056/NEJMcibr0911557, 20147723.
2. Van Hemelen D, Van Oosterhout AJM. Adjuvants for immunotherapy: lost in translation?. Clinical & Experimental Allergy 2009, 39:1783-1785. 10.1111/j.1365-2222.2009.03396.x, 21698849.
3. Ahlers JD, Belyakov IM. Strategies for optimizing targeting and delivery of mucosal HIV vaccines. European Journal of Immunology 2009, 39:2657-2669. 10.1002/eji.200939269, 19609978.
4. Cunningham AL, Carbone F, Geijtenbeek TBH. Langerhans cells and viral immunity. European Journal of Immunology 2008, 38:2377-2385. 10.1002/eji.200838521, 18792031.
5. Piacentini L, Fenizia C, Naddeo V, Clerici M. Not just sheer luck! Immune correlates of protection against HIV-1 infection. Vaccine 2008, 26:3002-3007. 10.1016/j.vaccine.2007.11.062, 18180082.
6. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006, 6:148-158. 10.1038/nri1777, 16491139.
7. Zinkernagel RM. On Immunity Against Infections and Vaccines: Credo 2004. Scandinavian Journal of Immunology 2004, 60:9-13. 10.1111/j.0300-9475.2004.01460.x, 15238068.
8. Liu L, Zhong Q, Tian T, Dubin K, Athale SK, Kupper TS. Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity. Nat Med 2010, 16:224-227. 10.1038/nm.2078, 3070948, 20081864.
9. Nottet H, van Dijk S, Fanoy E, Goedegebuure I, de Jong D, Vrisekoop N, van Baarle D, Boltz V, Palmer S, Borleffs J, Boucher C. HIV-1 can persist in aged memory CD4+ T lymphocytes with minimal signs of evolution after 8.3 years of effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2009, 50:345-353. 10.1097/QAI.0b013e318197eb04, 19214126.
10. Bello G, Casado C, Sandonis V, Alvaro-Cifuentes T, dos Santos CAR, Garcia S, Rodriguez C, del Romero J, Pilotto JH, Grinsztejn B, et al. Plasma Viral Load Threshold for Sustaining Intrahost HIV Type 1 Evolution. AIDS Research and Human Retroviruses 2007, 23:1242-1250. 10.1089/aid.2007.0074, 17961111.
11. Dinoso JB, Rabi SA, Blankson JN, Gama L, Mankowski JL, Siliciano RF, Zink MC, Clements JE. A Simian Immunodeficiency Virus-Infected Macaque Model To Study Viral Reservoirs That Persist during Highly Active Antiretroviral Therapy. The Journal of Virology 2009, 83:9247-9257.
12. Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, Cranmer L, O'Shea A, Callender M, Spivak A, Brennan T, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proceedings of the National Academy of Sciences 2009, 106:9403-9408.
13. Miura T, Brockman MA, Schneidewind A, Lobritz M, Pereyra F, Rathod A, Block BL, Brumme ZL, Brumme CJ, Baker B, et al. HLA-B57/B5801 Human Immunodeficiency Virus Type 1 Elite Controllers Select for Rare Gag Variants Associated with Reduced Viral Replication Capacity and Strong Cytotoxic T-Lymphotye Recognition. J Virol 2009, 83:2743-2755. 10.1128/JVI.02265-08, 2648254, 19116253.
14. Iannello A, Boulassel M-R, Samarani S, Debbeche O, Tremblay C, Toma E, Routy J-P, Ahmad A. Dynamics and Consequences of IL-21 Production in HIV-Infected Individuals: A Longitudinal and Cross-Sectional Study. J Immunol 184:114-126. 10.4049/jimmunol.0901967, 19949086.
15. De Maria A, Fogli M, Costa P, Murdaca G, Puppo F, Mavilio D, Moretta A, Moretta L. The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur J Immunol 2003, 33:2410-2418. 10.1002/eji.200324141, 12938217.
16. De Maria A, Moretta L. NK cell function in HIV-1 infection. Curr HIV Res 2008, 6:433-440. 10.2174/157016208785861221, 18855653.
17. Engram JC, Dunham RM, Makedonas G, Vanderford TH, Sumpter B, Klatt NR, Ratcliffe SJ, Garg S, Paiardini M, McQuoid M, et al. Vaccine-Induced, Simian Immunodeficiency Virus-Specific CD8+ T Cells Reduce Virus Replication but Do Not Protect from Simian Immunodeficiency Virus Disease Progression. J Immunol 2009, 183:706-717. 10.4049/jimmunol.0803746, 19542473.
18. Schell J, Rose NF, Fazo N, Marx PA, Hunter M, Ramsburg E, Montefiori D, Earl P, Moss B, Rose JK. Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge. Vaccine 2009, 27:979-986. 10.1016/j.vaccine.2008.12.017, 2661574, 19135115.
19. Appay V, Douek DC, Price DA. CD8+ T cell efficacy in vaccination and disease. Nat Med 2008, 14:623-628. 10.1038/nm.f.1774, 18535580.
20. Piacentini L, Biasin M, Fenizia C, Clerici M. Genetic correlates of protection against HIV infection: the ally within. Journal of Internal Medicine 2009, 265:110-124. 10.1111/j.1365-2796.2008.02041.x, 19093964.
21. Torheim EA, Ndhlovu LC, Pettersen FO, Larsen T-L, Jha AR, Torgersen KM, Kvale D, Nixon DF, Taskén K, Aandahl EM. Interleukin-10-secreting T cells define a suppressive subset within the HIV-1-specific T-cell population. European Journal of Immunology 2009, 39:1280-1287. 10.1002/eji.200839002, 2742768, 19384871.
22. Middendorp S, Nieuwenhuis EES. NKT cells in mucosal immunity. Mucosal Immunol 2009, 2:393-402. 10.1038/mi.2009.99, 19587641.
23. Allers K, Loddenkemper C, Hofmann J, Unbehaun A, Kunkel D, Moos V, Kaup F-J, Stahl-Hennig C, Sauermann U, Epple H-J, Schneider T. Gut Mucosal FOXP3+ Regulatory CD4+ T Cells and Non-Regulatory CD4+ T Cells are Differentially Affected by SIV Infection in Rhesus Macaques. J Virol JVI.01715-01709, 2838127, 20071575.
24. Torheim EA, Ndhlovu LC, Pettersen FO, Larsen T-L, Jha AR, Torgersen KM, Kvale D, Nixon DF, TaskÈn K, Aandahl EM. Interleukin-10-secreting T cells define a suppressive subset within the HIV-1-specific T-cell population. European Journal of Immunology 2009, 39:1280-1287. 10.1002/eji.200839002, 2742768, 19384871.
25. Becker C, Taube C, Bopp T, Becker C, Michel K, Kubach J, Reuter S, Dehzad N, Neurath MF, Reifenberg K, et al. Protection from graft-versus-host disease by HIV-1 envelope protein gp120-mediated activation of human CD4+CD25+ regulatory T cells. Blood 2009, 114:1263-1269. 10.1182/blood-2009-02-206730, 19439734.
26. Masur H, Ognibene F, Yarchoan R, Shelhamer J, Baird B, Travis W, Suffredini A, Deyton L, Kovacs J, Falloon J, et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med 1989, 111:223-231.
27. Saah A, Muñoz A, Kuo V, Fox R, Kaslow R, Phair J, Rinaldo CJ, Detels R, Polk B. Predictors of the risk of development of acquired immunodeficiency syndrome within 24 months among gay men seropositive for human immunodeficiency virus type 1: a report from the Multicenter AIDS Cohort Study. Am J Epidemiol 1992, 135:1147-1155.
28. Smith DK, Neal JJ, Holmberg SD. Unexplained Opportunistic Infections and CD4+ T-Lymphocytopenia without HIV Infection -- An Investigation of Cases in the United States. New England Journal of Medicine 1993, 328:373-379. 10.1056/NEJM199302113280601, 8093633.
29. Bunders M, Cortina-Borja M, Newell M, Study EC. Age-related standards for total lymphocyte, CD4+ and CD8+ T cell counts in children born in Europe. Pediatr Infect Dis J 2005, 24:595-600. 10.1097/01.inf.0000168835.01233.64, 15998999.
30. Data Collection on Adverse Events of Anti HIVDSG Changes Over Time in Risk Factors for Cardiovascular Disease and Use of Lipid-Lowering Drugs in HIV-Infected Individuals and Impact on Myocardial Infarction. Clinical Infectious Diseases 2008, 46:1101-1110. 10.1086/528862, 2702541, 18461712, Data Collection on Adverse Events of Anti HIVDSG.
31. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, Monforte ADA, Friis-M√∏ller N, et al. Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. Journal of Infectious Diseases 201:318-330. 10.1086/649897, 20039804.
32. Cinque P, Koralnik IJ, Gerevini S, Miro JM, Price RW. Progressive multifocal leukoencephalopathy in HIV-1 infection. The Lancet Infectious Diseases 2009, 9:625-636. 10.1016/S1473-3099(09)70226-9, 2919371, 19778765.
33. Crowe S, Carlin J, Stewart K, Lucas C, Hoy J. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J Acquir Immune Defic Syndr 1991, 4:770-776.
34. Girardi E, Antonucci G, Armignacco O, Salmaso S, Ippolito G. Tuberculosis and AIDS: a retrospective, longitudinal, multicentre study of Italian AIDS patients. Italian group for the study of tuberculosis and AIDS (GISTA). J Infect 1994, 28:261-269. 10.1016/S0163-4453(94)91693-4, 8089515.
35. Guech-Ongey M, Simard EP, Anderson WF, Engels EA, Bhatia K, Devesa SS, Mbulaiteye SM. AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology?. Blood 2010, 116:5600-5604. 10.1182/blood-2010-03-275917, 20813897.
36. Maurer T, Ponte M, Leslie K. HIV-Associated Kaposi's Sarcoma with a High CD4 Count and a Low Viral Load. New England Journal of Medicine 2007, 357:1352-1353. 10.1056/NEJMc070508, 17898112.
37. D'Souza G, Wiley D, Li X, Chmiel J, Margolick J, Cranston R, Jacobson L. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2008, 48:491-499. 10.1097/QAI.0b013e31817aebfe, 18614927.
38. Dorrucci M, Suligoi B, Serraino D, Tirelli U, Rezza G, Study IH-S. Incidence of invasive cervical cancer in a cohort of HIV-seropositive women before and after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001, 4.
39. Ghosn J, Flandre P, Cohen-Codar I, Girard PM, Chaix ML, Raffi F, Dellamonica P, NgoVan P, Norton M, Delfraissy JF, et al. Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial. HIV Medicine 11:137-142. 10.1111/j.1468-1293.2009.00752.x, 19682100.
40. The Strategies for Management of Antiretroviral Therapy Study G Major Clinical Outcomes in Antiretroviral Therapy (ART)'ÄìNaive Participants and in Those Not Receiving ART at Baseline in the SMART Study. Journal of Infectious Diseases 2008, 197:1133-1144. 10.1086/586713, 18476292, The Strategies for Management of Antiretroviral Therapy Study G.
41. Maggiolo F, Airoldi M, Callegaro A, Martinelli C, Dolara A, Bini T, Gregis G, Quinzan G, Ripamonti D, Ravasio V, Suter F. CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART. AIDS 2009, 27:799-807. 710.1097/QAD.1090b1013e328321b328375e.
42. Mussini C, Bedini A, Borghi V, Guaraldi G, Esposito R, Barchi E, Enilia R, Cozzi-Lepri A, Philips A, Ortolani P, et al. CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 × 106 cells/l. AIDS 2005, 19:287-294. 10.1097/01.aids.0000186019.47297.0d, 15718839.
43. Bozzano F, Nasi M, Bertoncelli L, Nemes E, Prati F, Marras F, Mussini C, Moretta L, Cossarizza A, De Maria A. NK-cell phenotype at interruption underlies widely divergent duration of CD4+-guided antiretroviral treatment interruption. International Immunology 23:109-118. 10.1093/intimm/dxq462, 21216830.
44. Zoufaly A, an der Heiden M, Kollan C, Bogner JR, Fätkenheuer G, Wasmuth JC, Stoll M, Hamouda O, van Lunzen J, the ClinSurv Study G. Clinical Outcome of HIV-Infected Patients with Discordant Virological and Immunological Response to Antiretroviral Therapy. Journal of Infectious Diseases 203:364-371. 10.1093/jinfdis/jiq055, 21208929.
45. Watanabe H, Sekine H, Uruma T, Nagasaki S, Tsunoda T, Machida Y, Kobayashi K, Igarashi H. Increase of atypical lymphocytes expressing CD4+/CD45RO+ in an infectious mononucleosis-like syndrome associated with hepatitis A virus infection. Journal of Infection and Chemotherapy 2009, 15:187-190. 10.1007/s10156-009-0677-9, 19554404.
46. Chow Y-H, Chang H-W, Sia R, Chong P, Sia C. Tonsillar CD4⁺FOXP3⁺ T-regulatory cell dynamics in primary EBV infection. Immunologic Research 50:97-101. 10.1007/s12026-010-8174-x, 21125344.
47. Janols H, Bredberg A, Thuvesson I, Janciauskiene S, Grip O, Wullt M. Lymphocyte and monocyte flow cytometry immunophenotyping as a diagnostic tool in uncharacteristic inflammatory disorders. BMC Infectious Diseases 10:205. 10.1186/1471-2334-10-205, 2912311, 20626864.
48. Lugli E, Pinti M, Nasi M, Troiano L, Ferraresi R, Mussi C, Salvioli G, Patsekin V, Robinson JP, Durante C, et al. Subject classification obtained by cluster analysis and principal component analysis applied to flow cytometric data. Cytometry Part A 2007, 71A:334-344.
49. Bai F, Bellistrì G, Tincati C, Savoldi A, Pandolfo A, Bini T, Carpani G, Sinigaglia E, Marchetti G, dAM A. Reduced CD127 expression on peripheral CD4+ T cells impairs immunological recovery in course of suppressive highly active antiretroviral therapy. AIDS 2010, 24:2590-2593. 10.1097/QAD.0b013e32833f9d64, 20935556.
50. Bellistri GM, Casabianca A, Merlini E, Orlandi C, Ferrario G, Meroni L, Galli M, Magnani M, Monforte A, Marchetti G. Increased Bone Marrow Interleukin-7 (IL-7)/IL-7R Levels but Reduced IL-7 Responsiveness in HIV-Positive Patients Lacking CD4+ Gain on Antiviral Therapy. PLoS ONE 5:e15663. 10.1371/journal.pone.0015663, 3013120, 21209878.
51. Marziali M, De Santis W, Carello R, Leti W, Esposito A, Isgrò A, Fimiani C, Sirianni M, Mezzaroma I, Aiuti F. T-cell homeostasis alteration in HIV-1 infected subjects with low CD4 T-cell count despite undetectable virus load during HAART. AIDS 2006, 20:2033-2041. 10.1097/01.aids.0000247588.69438.fd, 17053349.
52. Vidal-Castineira JR, Lopez-Vazquez A, Diaz-Pena R, Alonso-Arias R, Martinez-Borra J, Perez R, Fernandez-Suarez J, Melon S, Prieto J, Rodrigo L, Lopez-Larrea C. Effect of Killer Immunoglobulin-Like Receptors in the Response to Combined Treatment in Patients with Chronic Hepatitis C Virus Infection. J Virol 2010, 84:475-481. 10.1128/JVI.01285-09, 2798445, 19846535.
53. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, et al. Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus. Gastroenterology 2010, 139:120-129. e118, 10.1053/j.gastro.2010.04.013, 20399780.
54. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, Shianna KV, Mottola L, Petruzzellis D, Bacca D, et al. An IL28B Polymorphism Determines Treatment Response of Hepatitis C Virus Genotype 2 or 3 Patients Who Do Not Achieve a Rapid Virologic Response. Gastroenterology 2010, 139:821-827. e821, 10.1053/j.gastro.2010.05.079, 20621700.
55. Long BR, Ndhlovu LC, Oksenberg JR, Lanier LL, Hecht FM, Nixon DF, Barbour JD. KIR3DS1 Conferral of Enhanced Natural Killer Cell Function in Early HIV-1 Infection. J Virol 2008, JVI.02449-02407.
56. Wong AHW, Williams K, Reddy S, Wilson D, Giddy J, Alter G, Ghebremichael M, Carrington M, Ndung'u T, Walker BD, et al. Alterations in Natural Killer Cell Receptor Profiles During HIV Type 1 Disease Progression Among Chronically Infected South African Adults. AIDS RESEARCH AND HUMAN RETROVIRUSES 2010, 26:459-469.
57. Fogli M, Costa P, Murdaca G, Setti M, Mingari MC, Moretta L, Moretta A, De Maria A. Significant NK cell activation associated with decreased cytolytic function in peripheral blood of HIV-1-infected patients. Eur J Immunol 2004, 34:2313-2321. 10.1002/eji.200425251, 15259029.
58. Clausen LN, Weis N, Astvad K, Schønning K, Fenger M, Krarup H, Bukh J, Benfield T. Interleukin-28B polymorphisms are associated with hepatitis C virus clearance and viral load in a HIV-1-infected cohort. Journal of Viral Hepatitis 2011, 18:e66-e74. 10.1111/j.1365-2893.2010.01392.x, 21070502.
59. Antonelli LRV, Mahnke Y, Hodge JN, Porter BO, Barber DL, DerSimonian R, Greenwald JH, Roby G, Mican J, Sher A, et al. Elevated frequencies of highly activated CD4+ T cells in HIV+ patients developing immune reconstitution inflammatory syndrome. Blood 2010, 116:3818-3827. 10.1182/blood-2010-05-285080, 20660788.
60. Boulware DR, Meya DB, Bergemann TL, Wiesner DL, Rhein J, Musubire A, Lee SJ, Kambugu A, Janoff EN, Bohjanen PR. Clinical Features and Serum Biomarkers in HIV Immune Reconstitution Inflammatory Syndrome after Cryptococcal Meningitis: A Prospective Cohort Study. PLoS Med 2010, 7:e1000384. 10.1371/journal.pmed.1000384, 3014618, 21253011.
61. Rudy BJ, Lindsey JC, Flynn PM, Bosch RJ, Wilson CM, Hughes ME, Douglas SD. Immune Reconstitution and Predictors of Virologic Failure in Adolescents Infected through Risk Behaviors and Initiating HAART: Week 60 Results from the PACTG 381 Cohort. AIDS Research and Human Retroviruses 2006, 22:213-221. 10.1089/aid.2006.22.213, 16545007.
62. Goulder PJ BM, Krausa P, McIntyre K, Crowley S, Morgan B, Edwards A, Giangrande P, Phillips RE, McMichael AJ. Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection. AIDS Res Hum Retroviruses 1996, 12:1691-1698. 10.1089/aid.1996.12.1691, 8959245.
63. Kaslow RA CM, Apple R, Park L, Muñoz A, Saah AJ, Goedert JJ, Winkler C, O'Brien SJ, Rinaldo C, Detels R, Blattner W, Phair J, Erlich H, Mann DL. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996, 2:405-411. 10.1038/nm0496-405, 8597949.
64. Flores-Villanueva PO, Yunis EJ, Delgado JC, Vittinghoff E, Buchbinder S, Leung JY, Uglialoro AM, Clavijo OP, Rosenberg ES, Kalams SA, et al. Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. Proceedings of the National Academy of Sciences 2001, 98:5140-5145.
65. Costello C, Tang J, Rivers C, Karita E, Meizen-Derr J, Allen S, Kaslow RA. HLA-B5703 independently associated with slower HIV-1 disease progression in Rwandan women. AIDS 1999, 13:1990. 10.1097/00002030-199910010-00031, 10513667.
66. Boulet S, Sharafi S, Simic N, Bruneau J, Routy J-P, Tsoukas CM, Bernard NF. Increased proportion of KIR3DS1 homozygotes in HIV-exposed uninfected individuals. AIDS 2008, 22:595-599. 510.1097/QAD.1090b1013e3282f1056b1023, 10.1097/QAD.0b013e3282f56b23, 18317000.
67. Ravet S, Scott-Algara D, Bonnet E, Tran HK, Tran T, Nguyen N, Truong LX, Theodorou I, Barré-Sinoussi F, Pancino G, Paul P. Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals. Blood 2007, 109:4296-4305. 10.1182/blood-2006-08-040238, 17272507.
68. Guerini FR, Lo Caputo S, Gori A, Bandera A, Mazzotta F, Uglietti A, Zanzottera M, Maserati R, Clerici M. Under Representation of the Inhibitory KIR3DL1 Molecule and the KIR3DL1+/BW4+ Complex in HIV Exposed Seronegative Individuals. Journal of Infectious Diseases 2011, 203:1235-1239. 10.1093/infdis/jir020, 21398398.
69. Boulet S, Kleyman M, Kim JYJ, Kamya P, Sharafi S, Simic N, Bruneau J, Routy J-P, Tsoukas CM, Bernard NF. A combined genotype of KIR3DL1 high expressing alleles and HLA-B57 is associated with a reduced risk of HIV infection. AIDS 2008, 22:1487-1491. 1410.1097/QAD.1480b1013e3282ffde1487e, 10.1097/QAD.0b013e3282ffde7e, 18614872.
70. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, et al. Association between presence of HLA-B5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. The Lancet 2002, 359:727-732.
71. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, Goedert JJ, O'Brien TR, Jacobson LP, Kaslow R, et al. Contrasting Genetic Influence of CCR2 and CCR5 Variants on HIV-1 Infection and Disease Progression. Science 1997, 277:959-965. 10.1126/science.277.5328.959, 9252328.
72. Hendrickson SL, Jacobson LP, Nelson GW, Phair JP, Lautenberger J, Johnson RC, Kingsley L, Margolick JB, Detels R, Goedert JJ, O'Brien SJ. Host Genetic Influences on Highly Active Antiretroviral Therapy Efficacy and AIDS-Free Survival. JAIDS Journal of Acquired Immune Deficiency Syndromes 2008, 48:263-271. 210.1097/QAI.1090b1013e31816fdc31815f.
73. Laurichesse JJ, Persoz A, Theodorou I, Rouzioux C, Delfraissy JF, Meyer L. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Δ32 deletion. HIV Medicine 2007, 8:213-219. 10.1111/j.1468-1293.2007.00455.x, 17461848.
74. Marchetti G, Gori A, Casabianca A, Magnani M, Franzetti F, Clerici M, Perno CF, Monforte A, Galli M, Meroni L. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. Aids 2006, 20:1727-1736. 10.1097/01.aids.0000242819.72839.db, 16931937.
75. Nemes E, Lugli E, Nasi M, Ferraresi R, Pinti M, Bugarini R, Borghi V, Prati F, Esposito R, Cossarizza A, Mussini C. Immunophenotype of HIV+ patients during CD4 cell-monitored treatment interruption: role of the IL-7/IL-7 receptor system. AIDS 2006, 20:2021-2032. 2010.1097/2001.aids.0000247575.0000241622.b0000247571, 10.1097/01.aids.0000247575.41622.b1, 17053348.